CytoSorbents Corporation announced that Dr. Eric G. Mortensen, M.D., Ph.D., will join CytoSorbents as Chief Medical Officer, starting full-time on June 1, 2017. Dr. Mortensen has led clinical development of key programs for some of the pharmaceutical companies in the world, including Pfizer's novel rheumatoid arthritis therapy, Xeljanz®, which has achieved approximately $1 billion in annual worldwide sales. He brings more than two decades of proven and successful clinical trial development expertise to the company, as well as a wealth of knowledge and experience in immunology, inflammation, and clinical medicine. CytoSorbents also announced that Dr. Robert H. Bartlett, M.D. will retire as Chief Medical Officer, but will continue working closely with the company as a consultant and as Co-chair of the Cardiac Surgery Advisory Board with Dr. Joseph Zwischenberger, M.D. through the next anticipated REFRESH 2 cardiac surgery trial.